Lekoklar

Clarithromycin, the active ingredient in Lekoklar, is a macrolide antibiotic presented as an oral dosage form for systemic use. It is employed to treat a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, and skin and soft‑tissue infections, in adult patients. The drug works by inhibiting bacterial protein synthesis, which limits bacterial growth.

GNH USA supplies Lekoklar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with established quality assurance processes and regulatory compliance across EU markets.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections of the respiratory tract, sinuses, skin and gastrointestinal system. - Community‑acquired pneumonia: effective in eradicating susceptible Streptococcus pneumoniae and atypical pathogens, improving clinical outcomes. - Acute bacterial sinusitis: reduces bacterial load and alleviates sinus inflammation, leading to symptom relief. - Acute bacterial bronchitis: targets common respiratory bacteria, helping to resolve cough and sputum production. - Skin and soft tissue infections: combats Staphylococcus aureus and Streptococcus species, promoting healing of cellulitis and abscesses. - Helicobacter pylori eradication: used in combination regimens to eliminate H. pylori infection and support ulcer healing.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often occurring after the first dose. - Diarrhea: loose stools that may be self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste perception. - Headache: mild to moderate headache episodes.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes. - QT prolongation: cardiac rhythm changes that can lead to arrhythmia. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Pseudomembranous colitis: inflammation of the colon due to toxin‑producing bacteria.

When prescribing Clarithromycin, clinicians should consider several precautionary measures to ensure safe use. - Assess liver function: evaluate hepatic status before initiating therapy. - Review cardiac history: avoid use in patients with known QT prolongation or arrhythmias. - Monitor renal function: dose adjustment may be needed in severe renal impairment. - Caution in pregnancy: limited data; use only if potential benefit outweighs risk. - Avoid concomitant use with drugs that inhibit CYP3A4: may increase Clarithromycin levels. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture.

Clarithromycin interacts with several medications; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of myopathy and rhabdomyolysis. - Certain antiarrhythmics (e.g., amiodarone, quinidine): may cause severe QT prolongation. - Ergot derivatives (e.g., ergotamine, dihydroergotamine): risk of vasospasm and ischemia. - Pimozide: increased plasma concentrations leading to neurotoxicity. - HIV protease inhibitors (e.g., ritonavir): heightened Clarithromycin exposure and toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: possible increase in serum levels, watch for toxicity. - Carbamazepine: reduced efficacy due to enzyme induction. - Oral contraceptives: potential decrease in hormonal effectiveness. - Phenytoin: altered plasma concentrations, monitor therapeutic levels.